AptaBio Therapeutics Inc. (KOSDAQ:293780)

Revenue by Segment

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2022
New Business Division - Product Sales (ODM)	209.82M	-
New business division - Product Sales (General)	61.74M	48.35M
New business division - Product Sales (General) Growth	27.69%	-
Research and Development Department - Reagent Sales	52.31M	-
Total	323.87M	48.35M
Total Growth	569.82%	-

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2022
South Korea	323.87M	48.35M
South Korea Growth	569.80%	-
Total	323.87M	48.35M
Total Growth	569.80%	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 13, 2026

Data Sources Report a data error